Drug Profile
Eculizumab biosimilar - Prestige BioPharma
Alternative Names: PBP 1603Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Prestige BioPharma
- Class Anti-inflammatories; Antiallergics; Antianaemics; Antiasthmatics; Antihypertensives; Antipsoriatics; Antirheumatics; Eye disorder therapies; Monoclonal antibodies; Neuroprotectants; Skin disorder therapies; Urologics
- Mechanism of Action Complement C5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Atypical Haemolytic Uraemic Syndrome; Paroxysmal nocturnal haemoglobinuria
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Atypical-haemolytic-uraemic-syndrome in Singapore (Parenteral)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Paroxysmal-nocturnal-haemoglobinuria in Singapore (Parenteral)
- 23 Dec 2020 Phase-I clinical trials in Atypical haemolytic uraemic syndrome in Singapore (Parenteral) (Prestige BioPharma pipeline, December 2020)